Showing 31-39 of 39 results for "".
- New Patient-Centered Panel Helps BioPharmX Define its Role in the Future of Dermatologyhttps://practicaldermatology.com/news/new-patient-centered-panel-helps-biopharmx-define-its-role-in-the-future-of-dermatology/2457721/BioPharmX Corporation has formed a Special Advisory Council of thought leaders from various disciplines to help the company embrace patient centricity in its products, pricing, and market access considerations. The advisors, who bring decades of experience in fields beyond dermatology—ranging from…
- Amgen Launches The Enbrel Mini Single-Dose Prefilled Cartridge With AutoTouch Reusable Autoinjectorhttps://practicaldermatology.com/news/amgen-launches-the-enbrel-mini-single-dose-prefilled-cartridge-with-autotouch-reusable-autoinjector/2457966/Amgen's Enbrel Mini with AutoTouch is now available in the United States. Awarded the Arthritis Foundation Ease of Use Commendation, this new and innovative delivery system provides an additional administration option for appropriate Enbrel patients. The AutoTouch reusable autoinjector has an ergo…
- FDA Approves Expanded Use Of Enbrel To Treat Children With Chronic Moderate-To-Severe Plaque Psoriasishttps://practicaldermatology.com/news/fda-approves-expanded-use-of-enbrel-to-treat-children-with-chronic-moderate-to-severe-plaque-psoriasis/2458383/The FDA has approved the supplemental Biologics License Application (sBLA) for the expanded use of Amgen's Enbrel (etanercept), making it the first and only systemic therapy to treat pediatric patients (ages 4-17) with chronic moderate-to-severe plaque psoriasis. The approval is based on results f…
- Imlygic Approved for Melanoma; Available in a Weekhttps://practicaldermatology.com/news/imlygic-approved-for-melanoma-available-in-a-week/2458834/The FDA has approved the Biologics License Application for Amgen’s Imlygic™ (talimogene laherparepvec), a genetically modified oncolytic viral therapy indicated for the local treatment of unresectable cutaneous, subcutaneous and nodal lesions in patients with melanoma recurrent after initial surger…
- Amgen Submits Marketing Authorization Application For Talimogene Laherparepvec To The European Medicines Agencyhttps://practicaldermatology.com/news/20140904-amgen_submits_marketing_authorization_application_for_talimogene_laherparepvec_to_the_european_medicines_agency/2459130/Amgen recently submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) via the centralized procedure for talimogene laherparepvec seeking approval for the treatment of adults with melanoma that is regionally or distantly metastatic. Talimogene laherparepvec is a…
- Rosacea Concierge Offers Patient Support and Resourceshttps://practicaldermatology.com/news/20130924-rosacea_concierge_offers_patient_support_and_resources/2459453/Bayer HealthCare recently launched Rosacea Concierge, a new resource for the estimated 16 million people living with rosacea. The new, easy-to-navigate www.RosaceaConcierge.com includes information on rosacea in the form of video tutorials from a team of experts, including a dermatologist, nutritio…
- Actress Cynthia Nixon Helps Americans to Come Face to Face with Rosaceahttps://practicaldermatology.com/news/20121014-actress_cynthia_nixon_wants_americans_to_come_face_to_face_with_rosacea/2459707/Some of the 16 million Americans affected by rosacea are not seeking therapy, but a new initiative encourages them to come "Face to Face" with the disease. Supported by Galderma in association with the National Rosacea Society National Rosacea Society, the "Face to Face with Rosacea Symposium" brou…
DermWireTV: Spevigo for GPP; Derms on Acne Experience; IFPA Takes PsO to the Gaming World; La Roche-Posay at the US Open
https://practicaldermatology.com/topics/skin-cancer-photoprotection/dermwiretv-spevigo-for-gpp-derms-on-acne-experience-ifpa-takes-pso-to-the-gaming-world-la-roche-posay-at-the-us-open/20136/Boehringer Ingelheim’s Spevigo is the first FDA-approved treatment option for generalized pustular psoriasis (GPP) flares in adults. Spesolimab is a novel, selective antibody that blocks the activation of the interleukin-36 receptor. Dermatologists, dermatology physician assistants, and dermatologyDermWireTV: Noble Educates on Self-Injection; AAD and DEF Meeting Updates
https://practicaldermatology.com/topics/practice-management/dermwiretv-noble-educates-on-self-injection-aad-and-def-meeting-updates/19645/Participants in a study by the company Noble show that the vast majority of patients—92%—would prefer to bring home a training device to practice with prior to starting self-injection. Noble creates trainers for autoinjectors intended to increase patient confidence and autonomy with self-managed tre
- Previous
- Next